[Effect of gefitinib on radiosensitivity of gastric cancer cell lines]
- PMID: 18076795
[Effect of gefitinib on radiosensitivity of gastric cancer cell lines]
Abstract
Background & objective: Epidermal growth factor receptor (EGFR) is expressed in most human epithelial cancers and is involved in the development of cancer cell resistance to irradiation. We used gefitinib, a selective EGFR tyrosine kinase inhibitor (EGFR-TKI), to investigate its effects and mechanisms in enhancing the radiosensitivity of human gastric cancer cell lines in vitro.
Methods: The expression of EGFR protein in 7 human gastric cell lines (MKN45, SGC7901, SNU-1, N87, AGS, SNU-16, and KATO-III) was determined by Western blot, in which 2 cell lines with high expression of EGFR were selected for additional test. The inhibitory effect of gefitinib on cell proliferation was measured by MTT assay. Cell survival was determined by clonogenic assay, and then the radiosensitivity parameters were calculated. The effects of gefitinib in combination with radiation on cell apoptosis and cell cycle distribution were analyzed by flow cytometry.
Results: Of the 7 gastric cancer cell lines, the expression of EGFR in MKN45 and SGC7901 cells were the highest. The 50% inhibition concentrations (IC(50)) of gefitinib were 0.4 mmol/L for MKN45 cells and 0.8 mmol/L for SGC7901 cells. Cell survival was significantly decreased with the elevation of gefitinib concentration or radiation dose (P<0.05). When treated with 0.1x and 0.2 x IC(50) of gefitinib, the radiosensitization enhancement ratios (SER) of MKN45 cells were 1.102 and 1.154, and those of SGC7901 cells were 1.092 and 1.176, respectively. Either gefitinib or radiation induced cell apoptosis, reduced the percentage of cells at S phase and increased the percentage of cells at G(2)/M phase (P<0.01).
Conclusions: Gefitinib followed by radiation could increase the radiosensitivity of MKN45 and SGC7901 cells with high expression of EGFR and inhibit cell proliferation, induce apoptosis, and alter cell phase distribution. Gefitinib could be a radiation sensitizer for gastric tumors with high expression of EGFR.
Similar articles
-
β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.World J Gastroenterol. 2015 Sep 14;21(34):9945-56. doi: 10.3748/wjg.v21.i34.9945. World J Gastroenterol. 2015. PMID: 26379399 Free PMC article.
-
Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.Mol Med Rep. 2014 Jun;9(6):2417-22. doi: 10.3892/mmr.2014.2082. Epub 2014 Mar 28. Mol Med Rep. 2014. PMID: 24682085
-
Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e43-52. doi: 10.1016/j.ijrobp.2011.11.037. Int J Radiat Oncol Biol Phys. 2012. PMID: 22516386
-
[Epidermal growth factor receptor and radiotherapy].Klin Onkol. 2008;21(6):338-47. Klin Onkol. 2008. PMID: 19382597 Review. Czech.
-
Modulating the tumor microenvironment to increase radiation responsiveness.Cancer Biol Ther. 2009 Nov;8(21):1994-2001. doi: 10.4161/cbt.8.21.9988. Epub 2009 Nov 3. Cancer Biol Ther. 2009. PMID: 19823031 Free PMC article. Review.
Cited by
-
Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization.Mol Cytogenet. 2011 Jun 20;4(1):14. doi: 10.1186/1755-8166-4-14. Mol Cytogenet. 2011. PMID: 21689422 Free PMC article.
-
Targeted therapy in gastrointestinal malignancies.J Carcinog. 2014 Feb 20;13:4. doi: 10.4103/1477-3163.127639. eCollection 2014. J Carcinog. 2014. PMID: 24737952 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous